Diametric Capital LP Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Diametric Capital LP purchased a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,147 shares of the company’s stock, valued at approximately $52,000. Diametric Capital LP owned about 0.05% of Fractyl Health at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Jane Street Group LLC bought a new stake in Fractyl Health in the third quarter valued at approximately $25,000. Parkside Financial Bank & Trust acquired a new stake in Fractyl Health during the 4th quarter worth $27,000. JPMorgan Chase & Co. raised its stake in Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after buying an additional 11,406 shares during the period. HighTower Advisors LLC bought a new position in Fractyl Health during the third quarter worth about $38,000. Finally, Raymond James Financial Inc. acquired a new position in Fractyl Health in the fourth quarter valued at about $34,000.

Fractyl Health Stock Performance

Shares of GUTS opened at $1.16 on Thursday. The firm’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $2.01. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. Fractyl Health, Inc. has a twelve month low of $1.10 and a twelve month high of $7.89. The firm has a market cap of $56.75 million, a P/E ratio of -0.10 and a beta of 0.30.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). On average, analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current fiscal year.

Insider Transactions at Fractyl Health

In other Fractyl Health news, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the sale, the insider now owns 153,544 shares in the company, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total transaction of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

Separately, Morgan Stanley dropped their price target on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.